{
  "nctId": "NCT03053180",
  "briefTitle": "Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir (r) - Ombitasvir, + Dasabuvir Without Ribavirin in Participants With Chronic Hepatitis C and Compensated Liver Cirrhosis in the Russian Federation",
  "officialTitle": "Real World Evidence Study of the Effectiveness of Paritaprevir/r - Ombitasvir, + Dasabuvir Without Ribavirin in Patients With Chronic HCV Gt1b Infection and Compensated Liver Cirrhosis in the RussIan FederaTion- An ObseRvational, MultI-CeNter Study (CITRIN)",
  "protocolDocument": {
    "nctId": "NCT03053180",
    "filename": "Prot_000.pdf",
    "label": "Study Protocol",
    "date": "2016-11-29",
    "uploadDate": "2018-11-15T14:27",
    "size": 6898418,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT03053180/document/Prot_000.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [],
  "studyType": "OBSERVATIONAL",
  "enrollmentInfo": {
    "enrollmentCount": 60,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2017-03-20",
    "completionDate": "2017-12-18",
    "primaryCompletionDate": "2017-12-18",
    "firstSubmitDate": "2017-02-08",
    "firstPostDate": "2017-02-15"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* 3DAA ABBVIE REGIMEN will be prescribed by physicians according to the routine clinical practice\n* Treatment-naïve or interferon (IFN)/ribavirin (RBV)-experienced participants with confirmed CHC Gt1b and compensated liver cirrhosis, receiving therapy with the interferon-free 3DAA ABBVIE REGIMEN initiated not earlier than 2 weeks before the enrollment or the initiation is planned not later than 2 weeks after the day of enrollment in accordance to standard of care and in line with the current local label\n* Participants must not be participating or intending to participate in a concurrent interventional therapeutic trial\n\nExclusion Criteria:\n\n* Co-administration ribavirin (RBV) with the 3DAA ABBVIE REGIMEN\n* Participants with Child Pugh B and C cirrhosis\n* Participants with a history of prior direct-acting antiviral agent (DAA) therapy\n* Any other contraindications to the administration of 3DAA ABBVIE REGIMEN according to the label",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "99 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Percentage of Participants Achieving Sustained Virological Response 12 Weeks Post-treatment (SVR12)",
        "description": "SVR12 was defined as hepatitis C virus (HCV) ribonucleic acid (RNA) levels less than 50 IU/mL 12 weeks after the last dose of study drug.",
        "timeFrame": "12 weeks after the last dose of study drug (week 24)"
      }
    ],
    "secondary": [
      {
        "measure": "Percentage of Participants Achieving Virological Response at End of Treatment (EoT)",
        "description": "Virological response is defined as HCV RNA less than 50 IU/mL.",
        "timeFrame": "End of treatment, maximum of 12 weeks"
      },
      {
        "measure": "Percentage of Participants With Relapse",
        "description": "Relapse was defined as participants with a virologic response (VR; HCV RNA \\< 50 IU/mL) at end of treatment (EOT) followed by HCV RNA ≥ 50 IU/mL at any time after the end of treatment.",
        "timeFrame": "End of treatment (week 12) and up to 12 weeks after the end of treatment."
      },
      {
        "measure": "Percentage of Participants With Breakthrough",
        "description": "Breakthrough was defined as at least one documented HCV RNA \\< 50 IU/mL followed by HCV RNA ≥ 50 IU/mL during treatment.",
        "timeFrame": "12 weeks"
      },
      {
        "measure": "Percentage of Participants With Failure to Suppress",
        "description": "Failure to suppress was defined as each measured on-treatment HCV RNA value ≥ 50 IU/mL.",
        "timeFrame": "12 weeks"
      },
      {
        "measure": "Percentage of Participants With Missing SVR12 Data",
        "timeFrame": "12 weeks after the last dose of study drug (week 24)"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 5,
      "otherCount": 0,
      "totalCount": 6
    },
    "studyDesign": {
      "phases": [],
      "isRandomized": false,
      "isMasked": true
    },
    "overallComplexityScore": 54,
    "complexityCategory": "Complex"
  },
  "collectionDate": "2025-09-22T02:30:24.206Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}